Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease

Functional imaging by repeated noninvasive scans of specific (18)F tracer distribution using a high-resolution small-animal PET scanner, the microPET, assessed the time course of alterations in energy utilization and dopamine receptors in rats with unilateral striatal quinolinic acid lesions. Energy utilization ipsilateral to the lesion, determined using scans of 2-deoxy-2-[(18)F]fluoro-d-glucose uptake, was compromised severely 1 week after intrastriatal excitotoxin injections. When the same rats were imaged 5 and 7 weeks postlesion, decrements in energy metabolism were even more prominent. In contrast, lesion-induced effects on dopamine D(2) receptor binding were more progressive, with an initial upregulation of [3-(2'-(18)F]fluoroethyl)spiperone binding apparent 1 week postlesion followed by a decline 5 and 7 weeks thereafter. Additional experiments revealed that marked upregulation of dopamine D(2) receptors consequent to quinolinic acid injections could be detected as early as 3 days after the initial insult. Postmortem markers of striatal GABAergic neurons were assessed in the same rats 7 weeks after the lesion: expression of glutamic acid decarboxylase and dopamine D(1) receptor mRNA, as well as [(3)H]SCH-23,390 and [(3)H]spiperone binding to dopamine D(1) and D(2) receptors, respectively, detected prominent decrements consequent to the lesion. In contrast, by 7 weeks postlesion [(3)H]WIN-35,428 binding to dopamine transport sites within the striatum appeared to be enhanced proximal to the quinolinic acid injection sites. The results demonstrate that functional imaging using the microPET is a useful technique to explore not only the progressive neurodegeneration that occurs in response to excitotoxic insults, but also to examine more closely the intricacies of neurotransmitter activity in a small animal model of HD.

[1]  Elsdon Storey,et al.  Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.

[2]  Garrett E. Alexander Basal ganglia , 1998 .

[3]  James F. Young,et al.  MicroPET: a high resolution PET scanner for imaging small animals , 1996, IEEE Nuclear Science Symposium Conference Record.

[4]  W. Low,et al.  Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's Disease , 1997, Neuroscience Research.

[5]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[6]  J. Joyce,et al.  Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: Localization to intrinsic neurons and not to neocortical afferents , 1987, Neuroscience.

[7]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Brotchi,et al.  Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. , 1994, Neurological research.

[9]  S. Snyder,et al.  3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. , 1978, European journal of pharmacology.

[10]  D. Hilt,et al.  ret receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways. , 1997, Neuroscience.

[11]  S. W. Davies,et al.  Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum , 1988, Neuroscience.

[12]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  N W Kowall,et al.  Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  S. Folstein,et al.  D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. , 1990, The Journal of neuropsychiatry and clinical neurosciences.

[15]  J. Leysen,et al.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. , 1982, Molecular pharmacology.

[16]  Joseph B. Martin,et al.  Huntington's Disease and Neurotoxins , 1992, Annals of the New York Academy of Sciences.

[17]  R. Albin,et al.  Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.

[18]  Paul Kinahan,et al.  Analytic 3D image reconstruction using all detected events , 1989 .

[19]  Joseph B. Martin,et al.  Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.

[20]  K Minematsu,et al.  Positron Emission Tomography for Quantitative Determination of Glucose Metabolism in Normal and Ischemic Brains in Rats: An Insoluble Problem by the Harderian Glands , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  S. Sesack,et al.  Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[23]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[24]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[25]  S. Cherry,et al.  Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Parent,et al.  The response of striatal neuropeptide Y and cholinergic neurons to excitatory amino acid agonists , 1988, Brain Research.

[27]  D. Graham,et al.  Specific alterations in local cerebral glucose utilization following striatal lesions , 1982, Brain Research.

[28]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[29]  F. Hefti,et al.  Cholinergic regulation of hippocampal brain-derived neurotrophic factor mRNA expression: Evidence from lesion and chronic cholinergic drug treatment studies , 1993, Neuroscience.

[30]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[31]  A. Reiner,et al.  Relative Survival of Striatal Projection Neurons and Interneurons after Intrastriatal Injection of Quinolinic Acid in Rats , 1994, Experimental Neurology.

[32]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[33]  C. Gerfen The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.

[34]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[35]  R. Derynck,et al.  Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor , 1998, Journal of neuroscience research.

[36]  D. Guilloteau,et al.  Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone. , 1993, Life sciences.

[37]  M. Levivier,et al.  Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. , 1998, Neurological research.

[38]  R. Schwarcz,et al.  Intracerebral quinolinic acid injection in the rat: Effects on dopaminergic neurons , 1986, Brain Research.

[39]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[40]  Makler Pt,et al.  Bone scintigraphy: differentiating benign cortical irregularity of the distal femur from malignancy. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[42]  Joseph B. Martin,et al.  Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions , 1989, Synapse.

[43]  D. Schoepp,et al.  Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter , 1992, Neurochemistry International.

[44]  F. Gage,et al.  Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum , 1984, Nature.

[45]  J. Penney,et al.  Huntingtin localization in brains of normal and Huntington's disease patients , 1997, Annals of neurology.

[46]  S. Snyder,et al.  Drug and neurotransmitter receptors in the brain. , 1984, Science.

[47]  Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade. , 1995 .

[48]  G. Paxinos The Rat nervous system , 1985 .

[49]  D. Brooks,et al.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.

[50]  C. Ross,et al.  Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.

[51]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[52]  S. Tatter,et al.  Effects of striatal excitotoxicity on huntingtin-like immunoreactivity , 1995 .

[53]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[54]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[55]  D. Hilt,et al.  Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid , 1997, Neuroscience.

[56]  E. Azmitia,et al.  Rapid serotonergic fiber sprouting in response to ibotenic acid lesion in the striatum and hippocampus. , 1995, Brain research. Developmental brain research.

[57]  D. Brooks,et al.  Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.

[58]  J. Penney,et al.  Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study , 1992, Neuroscience.

[59]  Dennis P. Nelson,et al.  Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum , 1997, Journal of neurochemistry.

[60]  B. Rosen,et al.  PET- and MRI-Based Assessment of Glucose Utilization, Dopamine Receptor Binding, and Hemodynamic Changes after Lesions to the Caudate-Putamen in Primates , 1994, Experimental Neurology.

[61]  P. Sanberg,et al.  Differential loss of neurochemical markers following quinolinic acid-induced lesions of rat striatum , 1991, Experimental Neurology.

[62]  Osman Ratib,et al.  Interactive user-friendly image analysis of cardiac PET images on a low cost desktop computer , 1991, [1991] Proceedings Computers in Cardiology.

[63]  R. Hichwa,et al.  PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.

[64]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[65]  T. Chase,et al.  D-1 dopamine receptor changes after striatal quinolinic acid lesion. , 1987, European journal of pharmacology.

[66]  D. Hilt,et al.  Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease , 1997, Neuroscience.

[67]  Roger N. Gunn,et al.  Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.

[68]  S. Folstein,et al.  Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.

[69]  D. Riche,et al.  A Primate Model of Huntington'S Disease: Functional Neural Transplantation and Ct-Guided Stereotactic Procedures , 1992, Cell transplantation.